Fig. 1: Patient outcome in context of GEP and chromosomal high-risk markers and their respective frequencies and distribution in Myeloma XI. | Leukemia

Fig. 1: Patient outcome in context of GEP and chromosomal high-risk markers and their respective frequencies and distribution in Myeloma XI.

From: Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients

Fig. 1: Patient outcome in context of GEP and chromosomal high-risk markers and their respective frequencies and distribution in Myeloma XI.

Kaplan–Meier plot of Myeloma XI trial patients (n = 329) in context of SKY92 risk profiling for (a) PFS, (b) OS from maintenance randomization, with survival curves for patients randomized to lenalidomide or observation plotted separately. Log-rank P values displayed. c, d Kaplan–Meier plots of molecular risk groups defined by absence of any high-risk marker, presence of a single genetic risk marker, presence of either double-hit or SKY92 high-risk or combined double-hit and SKY92 high-risk for c PFS, d OS from induction randomization. e Venn diagram of patients with tumors positive for validated genetic risk markers adverse translocations, gain(1q), del(17p), SKY92 GEP high-risk. % is relative to 188 patients with high-risk lesions, (%) relative to all patients (n = 329) in the study. Frequency represented by gray color coding, with darker gray indicating higher frequency.

Back to article page